Notice of Results

RNS Number : 9105E

EKF Diagnostics Holdings PLC

04 March 2020

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

Notice of Results

Investor results briefing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.

Investor briefing

A briefing open to all investors will take place on Tuesday 24 March 2020 at No.1 Cornhill, London, EC3V 3ND from 4.30pm for a 4.45pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email  [e-mail]

EKF Diagnostics Holdings plc	www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman	Tel: [phone]
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nomad & Broker)	Tel: [phone]
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate Finance) Tom Salvesen (Corporate Broking)
Walbrook PR Limited  Tel: [phone] or [e-mail]
Paul McManus/ Lianne Cawthorne	Mob: [phone]

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

END

 

 

NORFZGGFNFGGGZM